PT1617876E - Tório-227 para utilização em radioterapia na doença do tecido mole - Google Patents

Tório-227 para utilização em radioterapia na doença do tecido mole Download PDF

Info

Publication number
PT1617876E
PT1617876E PT47275870T PT04727587T PT1617876E PT 1617876 E PT1617876 E PT 1617876E PT 47275870 T PT47275870 T PT 47275870T PT 04727587 T PT04727587 T PT 04727587T PT 1617876 E PT1617876 E PT 1617876E
Authority
PT
Portugal
Prior art keywords
thorium
radiotherapy
soft tissue
tissue disease
disease
Prior art date
Application number
PT47275870T
Other languages
English (en)
Portuguese (pt)
Inventor
Roy Larsen
Oyvind Bruland
Original Assignee
Algeta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0308731.9A external-priority patent/GB0308731D0/en
Application filed by Algeta As filed Critical Algeta As
Publication of PT1617876E publication Critical patent/PT1617876E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PT47275870T 2003-04-15 2004-04-15 Tório-227 para utilização em radioterapia na doença do tecido mole PT1617876E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0308731.9A GB0308731D0 (en) 2003-04-15 2003-04-15 Method of radiotherapy

Publications (1)

Publication Number Publication Date
PT1617876E true PT1617876E (pt) 2014-08-04

Family

ID=35385222

Family Applications (1)

Application Number Title Priority Date Filing Date
PT47275870T PT1617876E (pt) 2003-04-15 2004-04-15 Tório-227 para utilização em radioterapia na doença do tecido mole

Country Status (19)

Country Link
EP (1) EP1617876B1 (pl)
JP (2) JP5006032B2 (pl)
KR (2) KR101274867B1 (pl)
CN (1) CN100586484C (pl)
AU (1) AU2004229218B2 (pl)
BR (1) BRPI0409387B8 (pl)
CA (1) CA2522148C (pl)
CY (1) CY1115407T1 (pl)
DK (1) DK1617876T3 (pl)
EA (1) EA008195B1 (pl)
ES (1) ES2486845T3 (pl)
HK (1) HK1094150A1 (pl)
IL (1) IL171148A (pl)
MX (1) MXPA05010804A (pl)
NO (1) NO332931B1 (pl)
NZ (3) NZ543044A (pl)
PL (1) PL1617876T3 (pl)
PT (1) PT1617876E (pl)
ZA (1) ZA200507983B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101274867B1 (ko) * 2003-04-15 2013-06-13 알게타 에이에스 연조직 질환의 방사선 치료에 사용하기 위한 토륨-227
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
US11291680B2 (en) 2016-12-15 2022-04-05 Société des Produits Nestlé S.A. Compositions and methods that modulate white blood cells or neutrophils in a companion animal
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0429624T3 (da) * 1989-06-19 1994-05-30 Akzo Nobel Nv Radioimmunterapi under anvendelse af alfa-partikelemission
SG52470A1 (en) * 1992-04-13 1998-09-28 Dow Chemical Co Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
WO2001066155A2 (en) * 2000-02-25 2001-09-13 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
ITMI20022411A1 (it) * 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
KR101274867B1 (ko) * 2003-04-15 2013-06-13 알게타 에이에스 연조직 질환의 방사선 치료에 사용하기 위한 토륨-227

Also Published As

Publication number Publication date
JP2012051942A (ja) 2012-03-15
KR20060015507A (ko) 2006-02-17
JP5006032B2 (ja) 2012-08-22
MXPA05010804A (es) 2006-03-09
IL171148A (en) 2013-12-31
BRPI0409387A (pt) 2006-04-18
CY1115407T1 (el) 2017-01-04
ES2486845T3 (es) 2014-08-19
CN1805760A (zh) 2006-07-19
CA2522148A1 (en) 2004-10-28
NO20055390D0 (no) 2005-11-15
EP1617876A1 (en) 2006-01-25
BRPI0409387B8 (pt) 2021-05-25
AU2004229218B2 (en) 2009-05-07
NO332931B1 (no) 2013-02-04
BRPI0409387B1 (pt) 2021-05-11
ZA200507983B (en) 2007-03-28
EA008195B1 (ru) 2007-04-27
NZ606996A (en) 2014-08-29
CA2522148C (en) 2010-07-13
EA200501456A1 (ru) 2006-06-30
NO20055390L (no) 2006-01-16
NZ595758A (en) 2013-02-22
KR101274867B1 (ko) 2013-06-13
KR20110022743A (ko) 2011-03-07
PL1617876T3 (pl) 2015-03-31
HK1094150A1 (en) 2007-03-23
DK1617876T3 (da) 2014-07-21
AU2004229218A1 (en) 2004-10-28
NZ543044A (en) 2010-04-30
JP2006523664A (ja) 2006-10-19
JP5468597B2 (ja) 2014-04-09
EP1617876B1 (en) 2014-05-14
CN100586484C (zh) 2010-02-03

Similar Documents

Publication Publication Date Title
HK1094150A1 (en) Thorium-227 for use in radiotherapy of soft tissue disease
EP1731113A4 (en) MEDICAL TREATMENT KIT
GB0520687D0 (en) Skin treatment formulations
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
GB0324761D0 (en) Use of compounds in therapy
EP1736173A4 (en) MEANS FOR THE TREATMENT OF TISSUE DAMAGE AND THERAPEUTIC PROCEDURE
GB0320238D0 (en) Treatment of disease
AU2003223451A8 (en) Methods for ultrasonic imaging and treating diseased tissues
GB0411403D0 (en) Irradiating body tissue
GB0702859D0 (en) Dressing for tissue treatment
GB0300428D0 (en) Medical treatment
AU2003274649A8 (en) Diagnostic markers for therapeutic treatment
GB0215051D0 (en) Simulated body tissue
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject
GB2432322B (en) Gel for tissue treatment
GB0306165D0 (en) Medical treatment
GB0328870D0 (en) Characterising body tissue
GB0411400D0 (en) Imaging body tissue
GB0208194D0 (en) Treatment of disease
HU0302933D0 (en) Treatment of diseases
GB0302801D0 (en) Therapeutic methods and compositions for use therein
GB0326870D0 (en) Therapeutic methods and compositions for use therein
GB0310251D0 (en) Therapeutic methods and compositions for use therein
GB0303165D0 (en) Therapeutic methods and compositions for use therein
GB0310463D0 (en) Therapeutic agents for the treatment of bone conditions